



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/077,596	02/15/2002	Alan D. Snow	PROTEO.P18CI	2850
20985	7590	02/24/2005	EXAMINER	
FISH & RICHARDSON, PC 12390 EL CAMINO REAL SAN DIEGO, CA 92130-2081			JIANG, SHAOJIA A	
			ART UNIT	PAPER NUMBER
			1617	

DATE MAILED: 02/24/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/077,596	Applicant(s) SNOW ET AL.	
	Examiner Shaojia A. Jiang	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 14 October 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 28-41,55 and 56 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 28-41,55 and 56 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date <u>10/14/04, 5/18/04</u> | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on October 14, 2004 has been entered.

This Office Action is a response to Applicant's request for continued examination (RCE) filed October 14, 2004, and amendment and response to the Final Office Action (June 16, 2004), filed October 14, 2004 wherein claims 1-27 and 42-54 are cancelled.

Currently, claims 28-41 and 55-56 are pending in this application.

Claims 28-41 and 55-56 are currently under examination on the merits.

Priority

This application is a continuation in part of 10053625, and is a continuation in part of 09753313, and is a continuation in part of 09938987 which is a continuation of 09079829, which claims priority from Provisional Application 60046672, 60338721, 60339033, 60276866, and 60338969.

However, all these domestic priority documents upon which priority is claimed fail to provide adequate support under 35 U.S.C. 112 for the instant claims of this application for RCE since they do not disclose the essential feature of the invention

herein, the structural formula I and II in the instant Application, as indicated in the previous Office Action September 30, 2003.

Therefore, the effective and actual filing date of the instant claims is deemed to be the filing date of the instant application, February 15, 2002.

Applicant's remarks filed October 14, 2004 with respect to the provisional rejection made under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 14-15 of the copending Application No. 09/748,748 of record stated in the Office Action June 16, 2004 have been considered and found persuasive to remove this particular rejection since 09/748,748 is drawn to method claims using the specific compounds therein. Therefore, the said rejection is withdrawn.

Applicant's remarks filed October 14, 2004 with respect to the provisional rejection made under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 31-39 of the copending Application No. 10/053,625 of record stated in the Office Action June 16, 2004 have been considered and found persuasive to remove this particular rejection since 10/053,625 is drawn to the specific composition obtained by the specific method therein. Therefore, the said rejection is withdrawn.

Art Unit: 1617

Applicant's remarks filed October 14, 2004 with respect to the rejection made under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-18 of U.S. Patent No. 6,264,994 of record stated in the Office Action June 16, 2004 have been considered and found persuasive to remove this particular rejection since 10/053,625 is drawn to the specific composition obtained by the specific method therein. Therefore, the said rejection is withdrawn.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 28-41 and 55-56 are rejected under 35 U.S.C. 102(b) as being anticipated by Kuznicki et al. (5,681,569 of record).

Kuznicki et al. discloses a composition **comprising** green tea solids extracted from tea material, i.e., 0.01-0.35% flavanols or catechins wherein the catechin or a mixture of two or more the catechins are catechin, epicatechin, gallocatechin, epigallocatechin gallate and epicatechin gallate (see particularly col.3 lines 20-21 and 26-28), and a pharmaceutical carrier (i.e., water). See also abstract, col.2, lines 12-14; Example I, II, and III at col.10, and claims 1 and 5-6. Thus, the green tea composition of Kuznicki et al. **inherently** comprises **proanthocyanidins oligomers** having the formula I

Art Unit: 1617

and II herein and/or **procyanidins** such as the dimers and trimers of catechin and epicatechin herein.

The inherency of the green tea compositions containing proanthocyanidins and/or procyanidins is supported by the references by Hashimoto et al. (see "FC" in PTO-1449 submitted April 30, 2004),. Hashimoto et al. teach that proanthocyanidins are isolated from oolong tea (a well known green tea), and/or the flesh leaves of green teas therein, wherein proanthocyanidins can be degraded to catechin and epicatechins by hydrolysis. Most importantly the compounds identified by Hashimoto et al. in the green tea compositions are the instant compounds having the formula I or II (see Chart 2, the first two compounds on the top of page 3257). Morimoto et al. also teach that proanthocyanidins or procyanidins wherein proanthocyanidins can be degraded to catechins and epicatechins.

Kuznicki et al. also discloses the composition therein is therapeutically useful in improving cognitive performance (see col.3 line 33 in particular). The therapeutic effective amount of a catechin or mixture of catechins, within the instant claim (10-100mg/kg of body weight of the subject), is disclosed in the Example I and III (see col. 10 lines 1-41) as shown in the calculation below:

Example III discloses that a person can consume 835 cc (835 ml) of a beverage prepared according to Example I (see col.10 lines 40-41).

Since the water in the composition in Example I is 94.45%, the composition is aqueous solution. The density of water = 1 g/ml, thus the total amount of the composition in Example I is 835 g.

Art Unit: 1617

According to Example I, the effective amount of catechins (or flavanols)

$$= 835\text{g} \times 0.097\% \text{ (see col.10 line 15 in particular)} = 0.8099 \text{ g} = 809.9 \text{ mg}$$

OR in different calculation, according to Example I (see particularly at col.10 lines 6 and 13-14)

the effective amount of catechins

$$= 835\text{g} \times 0.35/100 \times 29/100 = 0.8475 \text{ g} = 847.5 \text{ mg.}$$

Since a standard person weight is 70 kg, the range of effective amounts of catechins is $10 \text{ mg/kg} \times 70 \text{ kg} = \underline{700 \text{ mg}}$ to $1000 \text{ mg/kg} \times 70 \text{ kg} = 70,000 \text{ mg}$.

Thus, the effective amount of catechins as exemplified in Example I in the composition of Kuznicki et al., 809.9 mg or 847.5 mg, is within the instant claimed range.

Kuznicki et al. also discloses that catechins therein are extracted from green teas or other plants, and isolated from green tea by methods well known to those in the art (see particularly at col.4 lines 6-14). Thus, their percentage purity herein is known to significantly exceed a proportion percentage of the catechin presence in a plant, which is an inherent property of the composition of Kuznicki et al. Kuznicki et al. also discloses that catechins can be prepared by synthetic chemical method or commercially available (see col.4 lines 14-17).

Thus, Kuznicki et al. anticipates claims 28-41 and 55-56.

Response to Argument

Applicant's arguments filed October 14, 2004 with respect to this rejection made under 35 U.S.C. 102(b) in the previous Office have been fully considered but they are not deemed persuasive to render the claimed invention patentable over the prior art. These remarks are believed to be adequately addressed by the rejection presented above.

Again, note that the transitional phrases "**comprising**" is employed in the instant claimed composition, i.e., the independent claim 28 reads "A pharmaceutical composition comprising a therapeutically effective amount of a proanthocyanidin, selected from..). Applicant is requested to note that the transitional term "comprising" is **inclusive or open-ended and does not exclude additional, unrecited elements or method steps**. See MPEP 2111.03.

Thus, the instant claimed composition read on the composition of Kuznicki et al. comprising green tea solids extracted from tea material, i.e., 0.01-0.35% flavanols or catechins wherein the catechin or a mixture of two or more the catechins are catechin, epicatechin, gallocatechin, epigallocatechin gallate and epicatechin gallate, and also proanthocyanidins oligomers having the formula I and II herein, because proanthocyanidins oligomers having the formula I and II herein are also extracted from green teas. Although the structural features of proanthocyanidins oligomers having the formula I and II herein have not been disclosed or identified by Kuznicki et al., proanthocyanidins oligomers having the formula I and II, are inherently **present** in the composition of Kuznicki et al. extracted from green teas. Note that the instant claimed

Art Unit: 1617

composition is not drawn to a composition consisting of proanthocyanidins oligomers having the formula I and II.

The burden is shifted to Applicant to show that the prior art product does not inherently possess proanthocyanidins and/or procyanidins as instantly claimed product.

Thus, Kuznicki et al. anticipates claims 28-41 and 55-56.

Claims 28, 31-41 and 55-56 are rejected under 35 U.S.C. 102(b) as being anticipated by JP 10245342 of record.

JP 10245342 discloses a pharmaceutical composition for diminishing the toxicity in nerve cells caused by β -amyloid protein comprising a catechin or two or more of catechin such as epigallocatechin gallate and epicatechin gallate prescribed in effective amounts (doses) of diminishing the toxicity of β -amyloid protein (see particularly page 1, the 2nd paragraph; claims 1-3 at page 1; page 2 [0001], [0002]), and a pharmaceutical carrier (i.e., water). See also page 7 [0028]; page 8 [0029]. Thus, the green tea composition in JP 10245342 inherently comprises proanthocyanidins oligomers having the formula I and II herein and/or procyanidins such as the dimers and trimers of catechin and epicatechin herein since catechins are known to encompass these compounds which are known to be isolated from green tea, as discussed above based on the references by Hashimoto et al., and Morimoto et al.

JP 10245342 also discloses that catechins therein are extracted from teas or other plants, and isolated and purified by HPLC (see page 6 [0027]). Thus, their percentage purity herein is known to significantly exceed a proportion percentage of the

Art Unit: 1617

catechin presence in a plant, and substantially pure isolated, which is an inherent property of the composition therein.

Thus, JP 10245342 anticipates claims 28, 31-41 and 55-56.

Applicant's arguments filed October 14, 2005 with respect to this rejection made under 35 U.S.C. 102(b) in the previous Office have been fully considered but they are not deemed persuasive to render the claimed invention patentable over the prior art for the same rationale discussed in the rejection anticipated by Kuznicki et al.

Claims 28, 31-41 and 55-56 are rejected under 35 U.S.C. 102(b) as being anticipated by Hashimoto et al. of record in PTO-1449 submitted April 30, 2004.

Hashimoto et al. discloses a composition comprising a catechin or two or more of catechins such as epigallocatechin and dimers and proanthocyanidins (having the formula I and II herein) and/or procyanidins such as the dimers and trimers of catechin and epicatechin in effective amounts, and a pharmaceutical carrier (i.e., water). See abstract. Thus, the oolong tea composition in Hashimoto et al. comprises the instant compounds herein since these compounds are known to be isolated from oolong tea. Most importantly the compounds identified by Hashimoto et al. in the green tea compositions are the instant compounds having the formula I or II (see Chart 2, the first two compounds on the top of page 3257).

Hashimoto et al. also discloses that proanthocyanidins are extracted from teas or other plants, and isolated (see page 6 [0027]). Thus, their percentage purity herein is known to significantly exceed a proportion percentage of the catechin presence in a

Art Unit: 1617

plant, and substantially pure isolated, which is an inherent property of the composition therein.

Thus, Hashimoto et al. anticipates claims 28, 31-41 and 55-56.

Applicant's arguments filed October 14, 2004 with respect to this rejection made under 35 U.S.C. 102(b) in the previous Office have been fully considered but they are not deemed persuasive to render the claimed invention patentable over the prior art. These remarks are believed to be adequately addressed by the rejection presented above.

Claims 28, 31-41 and 55-56 are rejected under 35 U.S.C. 102(b) as being anticipated by Morimoto et al. (PTO-892).

Morimoto et al. discloses a composition comprising a catechin or two or more of catechins such as epigallocatechin and dimers and procyanidins (having the formula I and II herein) such as the dimers and trimers of catechin and epicatechin in effective amounts, and a pharmaceutical carrier (i.e., water). See abstract, page 908-909. Most importantly the compounds identified by Morimoto et al. are the instant compounds having the formula I or II (see page 909, Compound 3 and page 908).

Thus, Morimoto et al. anticipates claims 28, 31-41 and 55-56.

Claims 28, 31-41 and 55-56 are rejected under 35 U.S.C. 102(b) as being anticipated by Hatano et al. for reasons of record stated in the Office Action dated September 30, 2003.

Hatano et al. discloses a composition for anti-HIV comprising or inherently comprising a catechin or two or more of catechins such as epigallocatechin and dimers or proanthocyanidins oligomers having the formula I and II herein and/or procyanidins such as the dimers and trimers of catechin and epicatechin in effective amounts, and a pharmaceutical carrier (i.e., water). See abstract. Thus, the composition in Hatano et al. inherently comprises the instant compounds herein since these compounds are known to be isolated from Camellia japonica plants. See abstract.

Hatano et al. also discloses that catechins therein are extracted from plants, and isolated (see page 6 [0027]). Thus, their percentage purity herein is known to significantly exceed a proportion percentage of the catechin presence in a plant, and substantially pure isolated, which is an inherent property of the composition therein.

Thus, Hatano et al. anticipates claims 28, 31-41 and 55-56.

Applicant's arguments filed October 14, 2004 with respect to this rejection made under 35 U.S.C. 102(b) in the previous Office have been fully considered but they are not deemed persuasive to render the claimed invention patentable over the prior art. These remarks are believed to be adequately addressed by the rejection presented above.


In view of the rejections to the pending claims set forth above, no claims are allowed.

Art Unit: 1617

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Jiang, whose telephone number is (571)272-0627. The examiner can normally be reached on Monday-Friday from 9:00 to 5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan, Ph.D., can be reached on (571)272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



S. Anna Jiang, Ph.D.
Primary Examiner
Art Unit 1617
February 17, 2005